Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903159 | 1.00 | CYP1A2 (0.35) | CYP1A2CYP2A6MAOBMAPTKMT2A | |
| SCHEMBL25323446 | 0.88 | GRM5 (0.33) | CYP1A2CYP2A6MAPTGRM5 | |
| SCHEMBL29428608 | 0.88 | GRM5 (0.33) | CYP1A2CYP2A6MAPTGRM5 | |
| SCHEMBL29903155 | 0.88 | GRM5 (0.36) | CYP1A2CYP2A6MAOBMAPTKMT2A | |
| SCHEMBL23409337 | 0.88 | GRM5 (0.36) | CYP1A2CYP2A6MAOBMAPTKMT2A | |
| SCHEMBL23043033 | 0.86 | NPC1 (0.33) | CYP1A2CYP2A6MAOBMAPTGRM5 | |
| SCHEMBL22208168 | 0.86 | GRM5 (0.33) | CYP1A2CYP2A6MAOBMAPTGRM5 | |
| SCHEMBL29418746 | 0.86 | GRM5 (0.33) | CYP1A2CYP2A6MAOBMAPTGRM5 | |
| SCHEMBL29966223 | 0.86 | GRM5 (0.32) | GRM5CYP2C19KDM4EALDH1A1CYP3A4 | |
| SCHEMBL29914173 | 0.86 | NPC1 (0.33) | CYP1A2CYP2A6MAOBMAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4347041-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769554-A | Small molecule inhibitors of KRAS muteins | 大鹏药品工业株式会社 | 2024-03-26 | — | — | CN | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| CN-116801883-A | Heteroaromatic ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| CN-115850267-A | Bridged ring compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115368383-A | Condensed nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022194192-A1 | HETEROAROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | KRAS, NRAS, HRAS | CYP1A2 4025/4885CYP2A6 2963/4885MAOB 4659/4885 |
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | KRAS, NRAS, HRAS | CYP1A2 4496/4885CYP2A6 4108/4885MAOB 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.